Roger Deck - Novadaq Technologies Vice President - Operations
| NVDQ Etf | 6.17 1.02 19.81% |
Mr. Roger Deck is Chief Financial Officer of Novadaq Technologies Inc., effect from 22 December 2014. He has over 20 years of operational and financial experience. Prior to being Chief Financial Officer, he was the VicePresident of Operations for NOVADAQ from June 2008 to December 2014. Mr. Deck previously served as the Chief Financial Officer of NOVADAQ from 2004 to June 2008. Mr. Deck served as Vice President, Financial Advisory Services at PricewaterhouseCoopers LLP from 2001 to 2003. From 2000 to 2001, Mr. Deck worked with J.R.Janus Merchant Brokers Ltd., an independent midmarket MA advisory firm. Prior to that role, Mr. Deck served as Vice President of Merchant Banking at Brascan Corporationrationration, starting in this position in 1996
| Tenure | 10 years |
| Address | 5090 Explorer Drive, Suite 202 L4W 4TW,Mississauga,CAN |
| Phone | 905-629-3822 |
| Web | www.novadaq.com |
| Issuer | Tuttle Capital Management |
| Inception Date | 2023-10-19 |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 12.79 Million |
| Asset Type | Equity |
| Category | Strategy |
| Focus | Single Stock |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | Commonwealth Fund Services, Inc. |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Josh Faddis | Veeva Systems Class | 42 | |
| Stephen Anderson | Laboratory of | N/A | |
| Herbert Fritch | Cigna Corp | 64 | |
| Sandra Vaart | Laboratory of | 64 | |
| Hemanth CFA | Venus Concept | 48 | |
| Kevin Pitzer | Mednax Inc | N/A | |
| David Erickson | Edwards Lifesciences Corp | N/A | |
| Frederic Lequient | Veeva Systems Class | 51 | |
| William Klitgaard | Laboratory of | 61 | |
| Scott Ullem | Edwards Lifesciences Corp | 57 | |
| Eric Palmer | Cigna Corp | 48 | |
| JeanLuc Lemercier | Edwards Lifesciences Corp | 67 | |
| C Richards | Mednax Inc | 50 | |
| AmirAli Talasaz | Guardant Health | 44 | |
| Dean Mirabella | Cigna Corp | N/A | |
| Suzanne Heck | Mednax Inc | N/A | |
| Michael Phillips | Cigna Corp | N/A | |
| Mark Brecher | Laboratory of | 57 | |
| Huimin Wang | Edwards Lifesciences Corp | 64 | |
| Matthew Manders | Cigna Corp | 58 | |
| Edwin Detrick | Cigna Corp | N/A | |
Novadaq Technologies Money Managers
| Anthony Griffiths, Independent Non-Executive Chairman of the Board | ||
| Patrice Merrin, Director | ||
| Lori Swalm, VP of Marketing | ||
| Thomas Wellner, Independent Director | ||
| Lisa Colleran, Director | ||
| Arun Menawat, President CEO, Director | ||
| Rick Mangat, Co-Founder, Sr. VP and General Manager | ||
| Harold Koch, Independent Director | ||
| David Martin, IR Contact Officer | ||
| Robert White, Director | ||
| Karen Licitra, Director | ||
| Aaron Davidson, Independent Director | ||
| Derrick Guo, General Counsel | ||
| William MacKinnon, Independent Director | ||
| Roger Deck, Vice President - Operations |
Novadaq Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Novadaq Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | (12.09) X | ||||
| Revenue | 80.07 M | ||||
| EBITDA | (50.47 M) | ||||
| Net Income | (52.91 M) | ||||
| Cash And Equivalents | 49.59 M | ||||
| Cash Per Share | 0.86 X | ||||
| Total Debt | 250 K | ||||
| Debt To Equity | 10.70 % | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | 1.54 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novadaq Technologies. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Novadaq Etf, please use our How to Invest in Novadaq Technologies guide.Note that the Novadaq Technologies information on this page should be used as a complementary analysis to other Novadaq Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
The market value of Novadaq Technologies is measured differently than its book value, which is the value of Novadaq that is recorded on the company's balance sheet. Investors also form their own opinion of Novadaq Technologies' value that differs from its market value or its book value, called intrinsic value, which is Novadaq Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novadaq Technologies' market value can be influenced by many factors that don't directly affect Novadaq Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novadaq Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novadaq Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novadaq Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.